Drug Profile
ZY GK1
Alternative Names: ZYGK1Latest Information Update: 21 Mar 2022
Price :
$50
*
At a glance
- Originator Cadila Healthcare
- Developer Zydus Lifesciences
- Class Antihyperglycaemics
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in India (PO)
- 24 Apr 2015 Phase I development in Type-2 diabetes mellitus is underway in India
- 31 Dec 2011 Phase-I clinical trials in Type-2 diabetes mellitus in India (PO)